Our future is shaped by innovation
Commitment to innovation is a central pillar of Dexcel’s culture. We devote resources to bring new pharmaceutical drugs to market and address patient needs. Our commitment to development and innovation in biopharmaceuticals spans therapeutic areas and modalities. We advance small molecules, siRNA, and biologics while also developing cost-effective generics
Development of complex generics and unique formulations
Dexcel Pharma utilizes in-house formulation know-how and drug delivery technologies to develop complex generic formulations and introduce unique product presentations. We leverage our regulatory expertise to enable new product development and identify niche product opportunities
Commitment to innovation
in RNA
Dexcel formed Dexoligo with the mission to translate the revolution of RNA therapeutics into novel medicines. Dexoligo is building an in-house pipeline of innovative medicines focused on siRNA therapeutics, oligonucleotides, and delivery solutions, to address areas of major unmet medical needs. Dexoligo focuses on areas of high unmet need where the use of siRNA therapeutics could be transformational
Reinventing the discovery and development of new medicines
In 2014, Dexcel became the founding investor of Roivant Sciences, with an aim to take an active part in developing new and highly innovative medicines. Roivant Sciences is a unique biopharmaceutical firm dedicated to realizing the full value of promising drug candidates by advancing them from late-stage clinical development to commercialization
